Get the Stockscreener App
4.80
0.41%
-0.02
Radiopharm Theranostics Ltd Adr stock is traded at $4.80, with a volume of 56,703.
It is down -0.41% in the last 24 hours and down -1.23% over the past month.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
See More
Previous Close:
$4.82
Open:
$4.88
24h Volume:
56,703
Relative Volume:
0.09
Market Cap:
$38.39M
Revenue:
$2.34M
Net Income/Loss:
$-24.85M
P/E Ratio:
-1.3836
EPS:
-3.4691
Net Cash Flow:
$-23.25M
1W Performance:
-3.61%
1M Performance:
-1.23%
6M Performance:
-16.52%
1Y Performance:
-37.17%
1-Day Range:
$4.64
$4.88
1-Week Range:
$4.64
$5.025
52-Week Range:
$3.4962
$16.25
Radiopharm Theranostics Ltd Adr Stock (RADX) Company Profile
Name
Radiopharm Theranostics Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare RADX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RADX
Radiopharm Theranostics Ltd Adr
|
4.87 | 38.00M | 2.34M | -24.85M | -23.25M | -3.4691 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
721.77 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Radiopharm Theranostics Ltd Adr Stock (RADX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-25 | Initiated | B. Riley Securities | Buy |
Radiopharm Theranostics Ltd Adr Stock (RADX) Latest News
Radiopharm Theranostics Doses First Patient in Phase 1/2a Trial of 177Lu-BetaBart - TipRanks
Radiopharm Theranostics LimitedSponsored ADR (NASDAQ:RADX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Hartford Multifactor Emerging Markets ETF (NYSEARCA:ROAM) Short Interest Up 110.6% in January - Defense World
Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Sees Significant Increase in Short Interest - Defense World
Short Interest in Azitra, Inc. (NYSEAMERICAN:AZTR) Expands By 112.1% - Defense World
GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update - Defense World
iShares Environmentally Aware Real Estate ETF (NASDAQ:ERET) Sees Significant Increase in Short Interest - Defense World
Radiopharm Theranostics (NASDAQ:RADX) versus Bolt Biotherapeutics (NASDAQ:BOLT) Head-To-Head Survey - Defense World
Radiopharm Theranostics (ASX:RAD) Prepares for Multiple 2026 Readouts with Firm Cash Position - Kalkine Media
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates - GlobeNewswire Inc.
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates - Sahm
Stevanato Group S.p.A. (NYSE:STVN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Radiopharm Theranostics (NASDAQ:RADX) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Radiopharm Theranostics Lifts Stake in MD Anderson Joint Venture to 87.5% as Lead B7H3 Drug Enters Clinic - TipRanks
RAD Increases Ownership in Radiopharm Ventures to 87.5% - Sahm
RADX: Interim Readout Achieves 92% Concordance - Research Tree
Equities Analysts Issue Forecasts for RADX FY2026 Earnings - Defense World
RADX FY2026 EPS Reduced by Brookline Capital Management - MarketBeat
Analysts’ Top Healthcare Picks: Foghorn Therapeutics (FHTX), Eton Pharmaceuticals (ETON) - The Globe and Mail
Radiopharm Theranostics (NASDAQ:RADX) Receives Buy Rating from B. Riley - Defense World
Buy Rating for Radiopharm Theranostics Limited Driven by Promising Clinical Developments and Growth Potential - TipRanks
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com India
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.62% - Investing.com UK
Radiopharm Theranostics (NASDAQ:RADX) Earns "Buy" Rating from B. Riley - MarketBeat
Dow Falls 50 Points; US Adds 64,000 Jobs In November - Benzinga
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
United States shares lower at close of trade; Dow Jones Industrial Average down 0.09% - Investing.com India
US stock market crash today: Dow, S&P 500, Nasdaq slide deep into the red — why is the stock market down today? - MSN
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.09% - Investing.com UK
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.09% - Investing.com
Radiopharm (RADX) Sees Slight Pessimism From Analysts - Finviz
US stock market crash today: Dow, S&P 500, Nasdaq slide deep into the red — why is the stock market down t - The Economic Times
Radiopharm Theranostics interim data shows 92% reach endpoint in RAD101 study - Investing.com Canada
Radiopharm Theranostics stock soars after positive brain metastases trial data - Investing.com
Radiopharm Theranostics stock soars after positive brain metastases trial data By Investing.com - Investing.com India
Get insights into the top gainers and losers of Monday's after-hours session. - ChartMill
Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases - Sahm
Book value per share of Radiopharm Theranostics Limited Sponsored ADR – NASDAQ:RADX - TradingView — Track All Markets
Analysts Conflicted on These Healthcare Names: MBX Biosciences, Inc. (MBX), Praxis Precision Medicines (PRAX) and Iovance Biotherapeutics (IOVA) - The Globe and Mail
Radiopharm Theranostics Announces Successful General Meeting Resolutions - TipRanks
Radiopharm Theranostics announces successful general meeting resolutions - MSN
B. Riley Lowers Radiopharm Theranostics (NASDAQ:RADX) Price Target to $13.00 - Defense World
Form 6-KReport of foreign issuer [Rules 13a-16 and 15d-16] - ADVFN
B. Riley Securities Sticks to Their Buy Rating for Perspective Therapeutics (CATX) - The Globe and Mail
Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer - Sahm
Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases - Sahm
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
Radiopharm Theranostics Ltd Adr Stock (RADX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):